This Event is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Key Event Title
Reduced complex sphingolipids
|Level of Biological Organization|
Key Event Components
Key Event Overview
AOPs Including This Key Event
|AOP Name||Role of event in AOP||Point of Contact||Author Status||OECD Status|
|CerS leads to NTDs||KeyEvent||Lola Bajard (send email)||Open for citation & comment|
Key Event Description
Complex sphingolipids are derived from ceramide and have a rather large structural diversity. They inlude, for example, sphingomyelin (SM) and glycosphingolipids such as gangliosides (GM), and are essential constituents or eukaryotic membranes (Kolter and Sandhoff, 2006). Considering their biologically relevant role as components of the cell membrane and thus basal functioning of cells, a decrease in sphingolipids may result in a variety of adverse effecfts. For example, sphinoglipids have been assigned a role in the pathogenesis of various metabolic diseases (sphingolipidoses), myocardial infarction, hypertension and diabetis mellitus (Borodzicz et al., 2015; Kolter and Sandhoff, 2006).
How It Is Measured or Detected
Domain of Applicability
Borodzicz, S., Czarzasta, K., Kuch, M., Cudnoch-Jedrzejewska, A., 2015. Sphingolipids in cardiovascular diseases and metabolic disorders. Lipids Health Dis. 14, 1–8. https://doi.org/10.1186/s12944-015-0053-y
Kolter, T., Sandhoff, K., 2006. Sphingolipid metabolism diseases. Biochim. Biophys. Acta - Biomembr. 1758, 2057–2079. https://doi.org/10.1016/j.bbamem.2006.05.027